Top executives weigh in at CIIE (V)

A1: Siemens Healthineers has been a long-standing associate of CIIE, and this year marks our fourth time participating in the CIIE event. The platform is, and always has been, an excellent opportunity for us to introduce ourselves and our offerings to a wider audience. We are showcasing Siemens Healthineers' latest breakthrough innovations, technologies, and solutions in the field of medical devices, such as the PET/CT scanner Biograph Vision Quadra and the robotic imaging solution Artis pheno.

This year, we expect to further expand our exchange and cooperation with customers and partners from various industrial sectors, so that we can jointly contribute to the development of China's healthcare sector and the "Healthy China" vision.

A2: CIIE does not merely offer business growth, but also provides a vital platform for multinational companies like Siemens Healthineers to help facilitate and foster international exchange. Thus, we are very happy to be part of this event.

A3: China of course displays enormous market potential. Our history with China dates back over a century, and we plan to leverage our expertise in healthcare technology and accelerate the introduction of innovations to grow in sync with the Chinese market.

Together with our partner, Zhangjiang Group, we have opened our Shanghai Innovation Center at the end of September. This center is designed to become a global innovation hub for healthcare technologies, while at the same time enabling our exploration of new opportunities in the extremely promising local Chinese market.

A4: We are seeing two major driving forces in the high-grade development of the medical and health industry. Firstly, the "14th Five-Year Plan" (2021-25) with its long-term goals for 2035 presents a strategic position that makes people's health a priority.

Secondly, with its population of 1.4 billion, China possesses an enormous healthcare market. Hence, as China gradually phases into an aging society and consumption levels become largely elevated, it can be expected that the demand for high-quality medical services will grow simultaneously.

A5: Siemens Healthineers has been deeply rooted in China with a large local footprint in R&D and manufacturing. For us, China plays a decisive role in our global strategy, to pioneer breakthroughs in healthcare for everyone.

The aforementioned Innovation Center that was recently inaugurated in Shanghai, is the most recent proof of our commitment to the Chinese market.

In 2018, we announced the construction of a plant for reagents used in blood testing in China with a total investment of 3 billion yuan ($468 million), to better address people's needs for upgraded health services in China. The new plant is expected to be completed and put into operation by September 2023.

A6: We see our role as trusted partner of the Chinese healthcare system and its patients by addressing the most pressing healthcare needs in China.

We are confident to introduce our innovations to the Chinese market, expand the accessibility of healthcare and support the 'Healthy China' cause.